ATE556058T1 - 1-(2h)-isochinolonderivat - Google Patents

1-(2h)-isochinolonderivat

Info

Publication number
ATE556058T1
ATE556058T1 AT05709816T AT05709816T ATE556058T1 AT E556058 T1 ATE556058 T1 AT E556058T1 AT 05709816 T AT05709816 T AT 05709816T AT 05709816 T AT05709816 T AT 05709816T AT E556058 T1 ATE556058 T1 AT E556058T1
Authority
AT
Austria
Prior art keywords
substituted
hydrogen atom
group
atom
hetero ring
Prior art date
Application number
AT05709816T
Other languages
English (en)
Inventor
Kazuo Hattori
Satoshi Niizuma
Takehiro Okada
Hiroyuki Eda
Kenji Tatsuno
Miyuki Yoshida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE556058T1 publication Critical patent/ATE556058T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05709816T 2004-02-06 2005-02-07 1-(2h)-isochinolonderivat ATE556058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004030885 2004-02-06
PCT/JP2005/001764 WO2005075431A1 (ja) 2004-02-06 2005-02-07 １−（２ｈ）−イソキノロン誘導体

Publications (1)

Publication Number Publication Date
ATE556058T1 true ATE556058T1 (de) 2012-05-15

Family

ID=34836016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05709816T ATE556058T1 (de) 2004-02-06 2005-02-07 1-(2h)-isochinolonderivat

Country Status (6)

Country Link
US (1) US8143274B2 (de)
EP (1) EP1724262B1 (de)
JP (1) JP4938311B2 (de)
AT (1) ATE556058T1 (de)
TW (1) TW200536830A (de)
WO (1) WO2005075431A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584485C (en) * 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
TWI389897B (zh) * 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
JP5368792B2 (ja) * 2005-07-29 2013-12-18 レスバーロジックス コーポレイション 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
US8034829B2 (en) * 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
RU2457203C2 (ru) * 2006-12-27 2012-07-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолона
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
US8735391B2 (en) 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
US8420668B2 (en) 2008-11-28 2013-04-16 Chugai Seiyaku Kabushiki Kaisha 1-(2H)-isoquinolone derivative
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US20120059026A1 (en) 2009-04-30 2012-03-08 University Of Medicine And Dentistry Of New Jersey Antimicrobial agents
CN101602725B (zh) * 2009-07-21 2012-07-11 浙江大学 六氢异喹啉酮类化合物的合成方法
KR20120100913A (ko) * 2009-10-13 2012-09-12 엠에스데 오쓰 베.베. 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체
FR2956816B1 (fr) * 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
EP2970143B1 (de) * 2013-03-15 2022-11-09 Johnson Matthey Public Limited Company Verfahren zur herstellung von alkylestern aus 4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1h-benzo[d-]imidazol-2-yl-)buttersäure
EP3044221B1 (de) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituierte isochinolin-1-on-verbindungen und deren therapeutische anwendung
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2015095446A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
MY194461A (en) 2015-11-06 2022-11-30 Neurocrine Biosciences Inc N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
KR20220100719A (ko) 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
CN109195957A (zh) 2016-02-25 2019-01-11 塔克西斯医药股份有限公司 合成方法和中间体
WO2018157856A1 (zh) * 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用
CA3058183A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates towardthe production of txa709
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2019232223A1 (en) 2018-05-30 2019-12-05 University Of Notre Dame Du Lac Hsp90 beta selective inhibitors
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
TW202134231A (zh) 2019-12-06 2021-09-16 美商紐羅克里生物科學有限公司 蕈毒受體4拮抗劑及使用方法
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
AU7484798A (en) 1997-05-13 1998-12-08 Octamer, Inc. Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
EP1396488A1 (de) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Kondensierte heterocyclische verbindung und deren medizinische verwendung
WO2005075432A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用

Also Published As

Publication number Publication date
US8143274B2 (en) 2012-03-27
WO2005075431A1 (ja) 2005-08-18
JPWO2005075431A1 (ja) 2007-10-11
EP1724262B1 (de) 2012-05-02
TW200536830A (en) 2005-11-16
EP1724262A4 (de) 2009-10-21
JP4938311B2 (ja) 2012-05-23
EP1724262A1 (de) 2006-11-22
US20070185160A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
EP1724262A4 (de) 1-(2h)-isochinolonderivat
EA200601235A1 (ru) Производные тиазола
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008114819A1 (ja) 新規アデニン化合物
WO2008108386A1 (ja) 医薬組成物
SE0400284D0 (sv) Novel compounds
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
ATE532770T1 (de) Imidazolderivat
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20064297L (no) Aminoalkoholforbindelse
EP1634874A4 (de) Imidazolidinderivate
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
EP1775289A4 (de) Neue imidazolidinderivate
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
FI20022159A0 (fi) Uusia farmaseuttisia yhdisteitä
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат